

Freedom of Information Request**Ref: UHB 18-176**

Date 20 April 2018

By Email

Dear Sir

Thank you for your request for information under the Freedom of Information Act 2000. The Trusts response is as follows:

1) In the past three months, how many metastatic hepatocellular carcinoma patients were treated with:

Sorafenib (Nexavar)	7
Other active systemic anti-cancer therapy	0
Other including palliative care (referrals to UH Bristol palliative care team)	**

Please note we have provided data for all patients with hepatocellular carcinoma who have been treated with Sorafenib below as we cannot reliably differentiate between metastatic and non-metastatic.

Please also note that not all of the patients in the disease categories below will have received palliative care from the hospital team – some will never have been admitted and will have received palliative care at home.

Where the figures are fewer than 5, this has been denoted by **. Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. Therefore under Section 40(2) of the Freedom of Information Act 2000, we will not be disclosing this information at this time. Section 40 is the exemption for personal information

2) In the past three months, how many metastatic renal cell carcinoma patients were treated with:

Sunitinib (Sutent)	16
Pazopanib (Votrient)	10
Everolimus (Afinitor)	0
Temsirolimus (Torisel)	0
Cabozantinib (Cometriq)	**
Nivolumab (Opdivo)	6

Axinitib (Inlyta)	7
Nivolumab + Ipilimumab (Opdivo + Yervoy)	0
Levatinib (Lenvima) + Everolimus (Afinitor)	0
Tivozanib (Fotivda)	**
Other active systemic anti-cancer therapy	**
Other including palliative care (referrals to UH Bristol palliative care team)	**

Please note we have provided data for all patients with hepatocellular carcinoma who have been treated with Sorafenib below as we cannot reliably differentiate between metastatic and non-metastatic.

Please also note that not all of the patients in the disease categories below will have received palliative care from the hospital team – some will never have been admitted and will have received palliative care at home.

Where the figures are fewer than 5, this has been denoted by **. Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. Therefore under Section 40(2) of the Freedom of Information Act 2000, we will not be disclosing this information at this time. Section 40 is the exemption for personal information

3) In the past 3 months, how many metastatic melanoma patients were treated with:

Pembrolizumab (Keytruda)	25
Nivolumab (Opdivo)	3
Ipilimumab (Yervoy)	**
Nivolumab + Ipilimumab (Opdivo + Yervoy)	0
Dabrafenib + Trametinib (Tafinlar + Mekinist)	9
Dabrafenib (Tafinlar)	**
Vemurafenib (Zelboraf)	**
Vemurafenib + cobimetinib (Zelboraf _ Cotellic)	0
Other active systemic anti-cancer therapy	8
Other including palliative care (referrals to UH Bristol palliative care team)	**

Please note we have provided data for all patients with hepatocellular carcinoma who have been treated with Sorafenib below as we cannot reliably differentiate between metastatic and non-metastatic.

Please also note that not all of the patients in the disease categories below will have received palliative care from the hospital team – some will never have been admitted and will have received palliative care at home.

Where the figures are fewer than 5, this has been denoted by **. Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. Therefore under Section 40(2) of the Freedom of Information Act 2000, we will not be disclosing this information at this time. Section 40 is the exemption for personal information

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary
University Hospitals Bristol NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely,

██████████
██████████